Clover Bio of Chengdu Completes $9.5 Million Series A for Biotech/Biosimilar Portfolio

Clover Biopharmaceuticals, a Chengdu biotech startup, completed a $9.5 million Series A financing led by Tianhe Life Sciences Venture Fund. Clover is developing a portfolio of novel biologic and differentiated biosimilar drug candidates. The company in-licensed rights to GenHunter Trimer-Tag© technology, which it uses to discover novel molecules for autoimmune diseases and cancer. It has also built a cGMP manufacturing capability for biologics, and expects to begin two clinical programs next year. The company plans to bring its novel, affordable drugs to China and global markets. More details.... Share this with colleagues: // //